1st Quarter - Amendment
WAXMAN STRATEGIES for 340B HEALTH
Firm
Client
Income
$39,000
Expenses
—
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report | Apr 20, 2026 | $25,000 | Replaced |
| 1st Quarter - Amendment (this page) | Apr 20, 2026 | $39,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues affecting the 340B drug pricing program; appropriations for 340B program
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN ROBINS New | — |
| JEREMY SHARP New | LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 |
| HENRY WAXMAN | US House of Representatives 1975 to 2015 |
Pharmacy PHA
Issues affecting the 340B drug pricing program; Appropriations for 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HELEN ROBINS New | — |
| JEREMY SHARP | LA,Rep Capps 2001-05 PSM, Sen HELP Comm 2007-10 LD, Sen Dodd 2010 DAS for Leg, HHS, 2011-13 Counselor, HHS, 2013-14 Dep Commissioner for Policy, FDA 2015-17 |
| HENRY WAXMAN | US House of Representatives 1975 to 2015 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.